U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H15NO2S
Molecular Weight 273.35
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARMODAFINIL

SMILES

NC(=O)C[S@@+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=YFGHCGITMMYXAQ-LJQANCHMSA-N
InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H15NO2S
Molecular Weight 273.35
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf | https://www.drugs.com/pro/armodafinil.html

Armodafinil is the R-enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness. Armodafinil is an indirect dopamine receptor agonist; both armodafinil and modafinil bind in vitro to the dopamine transporter and inhibit dopamine reuptake. Armodafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Once-daily armodafinil was generally well tolerated in adult patients with excessive sleepiness associated with OSA (despite treatment of the underlying condition), narcolepsy or SWSD.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
51.79 µM [IC50]
51.79 µM [IC50]
13.0 µM [Ki]
4.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROVIGIL

Approved Use

Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).

Launch Date

1998
Primary
PROVIGIL

Approved Use

Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).

Launch Date

1998
Primary
NUVIGIL

Approved Use

NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient.

Launch Date

2007
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.4 μg/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.5 μg/mL
250 mg 1 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10 μg/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
13.4 μg/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.8 μg/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 μg/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.9 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.1 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.4 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.2 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
4.1 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105.9 μg × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
136.1 μg × h/mL
250 mg 1 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
150.4 μg × h/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
189.5 μg × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
23.4 μg × h/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
56.2 μg × h/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
142.9 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
146 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
15.9 μg × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
40.6 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
43.8 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
75.9 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.8 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 21 years
n = 1
Health Status: unhealthy
Condition: idiopathic hypersomnia
Age Group: 21 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Stevens-Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Stevens-Johnson syndrome (1 patient)
Sources:
400 mg single, oral
Highest studied dose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, 21–40 years
n = 6
Health Status: healthy
Age Group: 21–40 years
Sex: M
Population Size: 6
Sources:
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
healthy, 21–40 years
n = 4
Health Status: healthy
Age Group: 21–40 years
Sex: M
Population Size: 4
Sources:
Disc. AE: Adverse event...
AEs leading to
discontinuation/dose reduction:
Adverse event
Sources:
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources:
Disc. AE: Headache...
AEs leading to
discontinuation/dose reduction:
Headache (1%)
Sources:
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p.6
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources: Page: p.6
Disc. AE: Rash, Angioneurotic edema...
AEs leading to
discontinuation/dose reduction:
Rash (2%)
Angioneurotic edema (1%)
Hyperhidrosis (1%)
Rash papular (1%)
Sources: Page: p.6
AEs

AEs

AESignificanceDosePopulation
Stevens-Johnson syndrome 1 patient
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy, 21 years
n = 1
Health Status: unhealthy
Condition: idiopathic hypersomnia
Age Group: 21 years
Sex: F
Population Size: 1
Sources:
Adverse event Disc. AE
400 mg 1 times / day steady, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
healthy, 21–40 years
n = 4
Health Status: healthy
Age Group: 21–40 years
Sex: M
Population Size: 4
Sources:
Headache 1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources:
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources:
Angioneurotic edema 1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p.6
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources: Page: p.6
Hyperhidrosis 1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p.6
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources: Page: p.6
Rash papular 1%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p.6
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources: Page: p.6
Rash 2%
Disc. AE
150 mg 1 times / day steady, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: steady
Dose: 150 mg, 1 times / day
Sources: Page: p.6
unhealthy
n = 645
Health Status: unhealthy
Population Size: 645
Sources: Page: p.6
PubMed

PubMed

TitleDatePubMed
Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice.
1995 Dec
Dopaminergic role in stimulant-induced wakefulness.
2001 Mar 1
Narcolepsy and psychopathology: is there an association?
2002 Jul
Acute behavioral and physiological effects of modafinil in drug abusers.
2002 Mar
Is psychosis exacerbated by modafinil?
2002 Mar
Modafinil for social phobia and amphetamine dependence.
2002 Nov
Temporal pattern of hippocampal high-frequency oscillations during sleep after stimulant-evoked waking.
2003
Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies.
2003 Apr
Modafinil in children with attention-deficit hyperactivity disorder.
2003 Aug
Modafinil for treatment of cognitive side effects of antiepileptic drugs in a patient with seizures and stroke.
2003 Jun
Modafinil increases histamine release in the anterior hypothalamus of rats.
2003 Mar 20
Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.
2003 May 1
Narcolepsy drug could be approved for wider use.
2003 Oct 4
You'll lose sleep over this pill.
2003 Sep 29
Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy.
2003 Sep-Oct
Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity.
2004 Aug
Modafinil treatment of excessive sedation associated with divalproex sodium.
2004 Jan
Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization.
2004 Nov 18
Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers.
2005
A double-blind, placebo-controlled trial of modafinil for cocaine dependence.
2005 Jan
[Effect of diazepam and modafinil on acute hepatic failure in mice].
2005 Jun
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study.
2006 Feb
Use of modafinil for the treatment of attention deficit/hyperactivity disorder.
2006 Oct
Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life.
2007
Psychostimulants and military operations.
2007 Apr
Acute chorea and hyperthermia after concurrent use of modafinil and tranylcypromine.
2007 Apr
Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants.
2007 Jul
Mechanisms of modafinil: A review of current research.
2007 Jun
Chest tightness and palpitations associated with modafinil and consumption of free glutamate.
2008 Apr
Modafinil: a review of neurochemical actions and effects on cognition.
2008 Jun
Smoked cocaine self-administration is decreased by modafinil.
2008 Mar
Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual.
2008 Oct
Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity.
2009 Aug
A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.
2009 Feb
How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion.
2009 Jun
Modafinil treatment of amphetamine abuse in adult ADHD.
2009 Jun
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.
2009 May
Open-label pilot study of modafinil for methamphetamine dependence.
2009 Oct
Modafinil for the treatment of cocaine dependence.
2009 Sep 1
[Modafinil in psychiatric disorders: the promising state reconsidered].
2010
Effects of modafinil on the sleep EEG depend on Val158Met genotype of COMT.
2010 Aug
Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse.
2010 Jun
Normalizing effects of modafinil on sleep in chronic cocaine users.
2010 Mar
Modafinil for bipolar depression with comorbid methamphetamine abuse.
2010 Mar-Apr
A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence.
2010 May
A retrospective review of supratherapeutic modafinil exposures.
2010 Sep
Armodafinil in the treatment of sleep/wake disorders.
2010 Sep 7
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

In Vivo Use Guide
Dosage in Narcolepsy and Obstructive Sleep Apnea (OSA) The recommended dosage of PROVIGIL (Modafinil ) for patients with narcolepsy or OSA is 200 mg taken orally once a day as a single dose in the morning.
Route of Administration: Oral
At high concentrations of modafinil (>/=100 uM), the mean activity of CYP2C9 in pooled human liver microsomes was decreased (up to 60%) relative to that in the solvent controls.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:34:52 GMT 2023
Edited
by admin
on Fri Dec 15 15:34:52 GMT 2023
Record UNII
V63XWA605I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ARMODAFINIL
INN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
ACETAMIDE, 2-((R)-(DIPHENYLMETHYL)SULFINYL)-
Systematic Name English
CEP-10953
Code English
ARMODAFINIL [WHO-DD]
Common Name English
NSC-751850
Code English
CEP-10952
Code English
CRL-40982
Code English
NUVIGIL
Brand Name English
ARMODAFINIL [USP-RS]
Common Name English
MODAFINIL, (R)-
Common Name English
(-)-2-((R)-(DIPHENYLMETHYL)SULFINYL)ACETAMIDE
Systematic Name English
NSC-758711
Code English
ARMODAFINIL [MART.]
Common Name English
2-[(R)-(Diphenylmethyl)sulfinyl]acetamide
Systematic Name English
R-(-)-MODAFINIL
Common Name English
armodafinil [INN]
Common Name English
ARMODAFINIL [ORANGE BOOK]
Common Name English
ARMODAFINIL [USAN]
Common Name English
ACETAMIDE, 2-((DIPHENYLMETHYL)SULFINYL)-, (-)-
Systematic Name English
ARMODAFINIL [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC N06BA13
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
NCI_THESAURUS C47795
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
LIVERTOX NBK548274
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
Code System Code Type Description
CAS
112111-43-0
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
PUBCHEM
9690109
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
DRUG CENTRAL
4501
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
INN
8474
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
CHEBI
77590
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
DRUG BANK
DB06413
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
LACTMED
Armodafinil
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
RXCUI
641465
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C65241
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
NSC
751850
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201192
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
RS_ITEM_NUM
1042758
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
WIKIPEDIA
ARMODAFINIL
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
SMS_ID
100000124335
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
DAILYMED
V63XWA605I
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID90920667
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
FDA UNII
V63XWA605I
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
EVMPD
SUB32249
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
NSC
758711
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
USAN
PP-67
Created by admin on Fri Dec 15 15:34:52 GMT 2023 , Edited by admin on Fri Dec 15 15:34:52 GMT 2023
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER
TARGET -> INHIBITOR
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC